Tocagen to Present Interim Results from Studies Evaluating Toca 511 & Toca FC at the Annual Meeting of the Society for Neuro-Oncology (SNO)

SAN DIEGO, Nov. 18, 2015 /PRNewswire/ -- Tocagen Inc., a clinical-stage, cancer-selective immunotherapy company, today announced that interim results from ongoing Phase 1 and preclinical studies of Toca 511 in combination with Toca FC will be presented at the 20^th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), to be held Nov. 19-22, 2015, in San Antonio, TX. An additional podium presentation will be presented at the SNO-SCIDOT Joint Conference on Therapeutic Delivery to the CNS, held Nov. 18-19 in San Antonio, TX.

Details of the podium and poster presentations at SNO are as follows:

Presentation Type: Podium
Title: Results of a dose escalation trial of Toca 511 with Toca FC in recurrent HGG undergoing repeat resection
Date and Time: Sunday, Nov. 22, 3:20-5:00 p.m. CT
Presenter: Michael A. Vogelbaum, M.D., Ph.D., professor of neurosurgery at the Cleveland Clinic

Abstract Number: DDEL-06
Title: Preliminary safety of Toca 511, a retroviral replicating vector, in patients with recurrent high grade glioma across three separate Phase 1 studies
Date and Time: Friday, Nov. 20, at 7:30 p.m. CT 
Lead Author: Steven N. Kalkanis M.D., chair of the department of neurosurgery and co-director of the Neuroscience Institute at Henry Ford Hospital

Abstract Number: DDEL-07
Title: Intravenous Toca 511 delivery leads to viral DNA in resected HGG
Date and Time: Friday, Nov. 20, at 7:30 p.m. CT 
Lead Author: Timothy Cloughesy, M.D., director of the University of California, Los Angeles, Neuro-Oncology Program

Abstract Number: DDEL-08
Title: Overall safety and efficacy in subjects with recurrent HGG treated across 2 Tocagen studies - Prognostic Factors associated with survival
Date and Time: Friday, Nov. 20, at 7:30 p.m. CT 
Lead Author: Joseph Landolfi, M.D., chief of neurology at JFK Neuroscience Institute and director of neuro-oncology at JFK Brain Tumor Center

Abstract Number: IMCT-04
Title: Toca 5: Phase 2/3 randomized, open-label study of Toca 511 with Toca FC versus standard of care in patients undergoing planned resection for recurrent high grade glioma (NCT02414165)
Date and Time: Friday, Nov. 20, at 7:30 p.m. CT 
Lead Author: Gelareh Zadeh, M.D., Ph.D., scientist at Labatt Brain Tumor Research Centre and adjunct scientist at The Hospital for Sick Children

Abstract Number: IMCT-05
Title: Combinability of Toca FC and Toca 511 with chemotherapy and targeted agents
Date and Time: Friday, Nov. 20, at 7:30 p.m. CT 
Lead Author: Santosh Kesari, M.D., Ph.D., director of neuro-oncology at Moores Cancer Center at UC San Diego Health

Abstract Number: SURG-10
Title: Transcranial Toca 511 followed by Toca FC in subjects with recurrent high grade glioma (HGG)
Date and Time: Friday, Nov. 20, at 7:30 p.m. CT 
Lead Author: Manish Aghi, M.D., Ph.D., associate professor of neurological surgery at University of California, San Francisco

Abstract Number: GENO-30
Title: Distinct gene expression profile that is not a known survival predictor in tumors from long-term high grade glioma survivors treated with a retroviral replicating vector encoding yeast cytosine deaminase
Date and Time: Saturday, Nov. 21, at 5:00 p.m. CT 
Lead Author: Derek Ostertag, Ph.D., department leader of R&D Diagnostics at Tocagen, Inc.

Details of the podium presentation at the SNO-SCIDOT Joint Conference on Therapeutic Delivery to the CNS are as follows:

Title: Clinical Development of a Retroviral Vector:  Delivery Questions
Date and Time: Wednesday Nov. 18, at 4:05 p.m. CT
Presenter: Manish Aghi, M.D., Ph.D., associate professor of neurological surgery at University of California, San Francisco

About Toca 511 & Toca FC

Tocagen's cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs) which are designed to selectively integrate into the DNA of cancer cells which then serve as factories for these RRVs to replicate and infect neighboring cancer cells, providing long-term presence of the therapeutic gene(s). Tocagen's lead product candidate is a combination of an investigational biologic, Toca 511, and an investigational small molecule drug, Toca FC, designed to be used together. Toca 511 is a proprietary injectable RRV that encodes a prodrug activator enzyme, cytosine deaminase (CD). Its selective delivery to cancer cells means that the infected cancer cells selectively carry the CD gene and produce CD protein. Toca FC is an orally administered, proprietary extended-release version of 5-FC, a prodrug that is inactive as an anti-cancer drug. Toca FC is converted into the active anti-cancer drug, 5-FU, at high concentrations in Toca-511-infected cancer cells that are producing CD protein. 5-FU is a well-established anti-cancer agent used effectively in many conventional chemotherapy settings. In addition to the direct killing of Toca 511-infected cancer cells, 5-FU kills neighboring uninfected cancer cells and myeloid derived suppressor cells (MDSCs) in the tumor.

About Tocagen Inc.

Tocagen is a clinical-stage, cancer-selective immunotherapy company focused on developing first-in-class, broadly-applicable product candidates designed to activate a patient's immune system against their own cancer from within. The company is developing its lead product candidate, Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma (HGG), a disease with significant unmet medical need. Tocagen has initiated the Phase 2 portion of a randomized, controlled Phase 2/3 clinical trial of Toca 511 & Toca FC in patients with recurrent HGG, which is designed to serve as a potential registrational trial. In 2016, Tocagen plans to initiate clinical trials of Toca 511 & Toca FC in patients with newly diagnosed HGG and other solid tumors. Tocagen obtained Fast Track designation from the U.S. Food and Drug Administration, for Toca 511 & Toca FC for the treatment of recurrent HGG and Orphan drug designation for the treatment of glioblastoma (GBM), a subset of HGG. For more information visit www.tocagen.com or follow @Tocagen.

Media Contact:
Monica May
Canale Communications
(619) 849-5383
[email protected]

SOURCE Tocagen Inc.

Related Links

http://www.tocagen.com